Peter Black, MD, discusses which patients are currently eligible for immunotherapy, how the indications are likely to expand, some of the common side effects of immunotherapy and their incidence, and the availability of tools to determine which patients are suitable candidates for treatment.
In the treatment of bladder cancer, the use of newer immunotherapy agents as second-line treatment and in patients who are ineligible for cisplatin-based chemotherapy is “the tip of the iceberg,” according to Peter Black, MD, of the University of British Columbia in Vancouver.
In the near future, look for these agents to be used earlier in the disease process, Dr. Black said.
In this video, Dr. Black discusses which patients are currently eligible for immunotherapy, how the indications are likely to expand, some of the common side effects of immunotherapy and their incidence, and the availability of tools to determine which patients are suitable candidates for treatment.
Dr. Black is a consultant/adviser to GenomeDx Biosciences, Janssen, Astellas, Amgen, Sitka, AbbVie, Bristol Myers Squibb, Bayer, Biosyent, Sanofi, Urogen, and Roche/Genentech. He conducts laboratory research for iProgen.
Cretostimogene grenadenorepvec reaches high complete response rate in NMIBC
May 3rd 2024The novel oncolytic immunotherapy cretostimogene grenadenorepvec induced complete responses (CRs) in three-fourths of patients with BCG unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, according to findings from the phase 3 BOND-003 trial (NCT04452591) presented at the 2024 AUA Annual Meeting.
Subcutaneous nivolumab meets coprimary pharmacokinetic end points for ccRCC
January 30th 2024Patients in the subcutaneous arm (n = 242) achieved a geometric mean Cavgd28 of 77.373μl/mL (90% CI, 74.555-80.297) compared with 36.875 μl/mL (90% CI, 35.565-38.235) in the IV arm (n = 245), for a geometric mean ratio of 2.098 μl/mL (90% CI, 2.001-2.200).